Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock OptionsZacks Investment Research • 12/23/20
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx ConferenceGlobeNewsWire • 11/16/20
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/04/20
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/29/20
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic DermatitisGlobeNewsWire • 10/20/20
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business HighlightsGlobeNewsWire • 08/07/20
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 08/06/20
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic DermatitisGlobeNewsWire • 07/07/20
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19GlobeNewsWire • 06/17/20
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/26/20
Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 InhibitorGlobeNewsWire • 01/09/20
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of DirectorsGlobeNewsWire • 01/08/20
Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/11/19